在研机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
1型糖尿病 | 临床3期 | 奥地利 | 2005-09-01 | |
1型糖尿病 | 临床3期 | 捷克 | 2005-09-01 | |
1型糖尿病 | 临床3期 | 芬兰 | 2005-09-01 | |
1型糖尿病 | 临床3期 | 法国 | 2005-09-01 | |
1型糖尿病 | 临床3期 | 德国 | 2005-09-01 | |
1型糖尿病 | 临床3期 | 希腊 | 2005-09-01 | |
1型糖尿病 | 临床3期 | 以色列 | 2005-09-01 | |
1型糖尿病 | 临床3期 | 意大利 | 2005-09-01 | |
1型糖尿病 | 临床3期 | 南非 | 2005-09-01 | |
1型糖尿病 | 临床3期 | 西班牙 | 2005-09-01 |
临床3期 | 457 | (DiaPep277) | 壓鑰膚鹹鹽遞壓襯廠鏇(淵繭構顧簾範鏇製衊窪) = 齋淵製顧憲糧鬱鏇膚鏇 觸襯鹹膚願繭選憲窪窪 (壓製艱餘廠憲壓網夢窪, 願淵憲鑰築壓觸蓋願鹽 ~ 鬱鬱範窪築遞膚獵廠繭) 更多 | - | 2016-06-06 | ||
Placebo (Placebo) | 壓鑰膚鹹鹽遞壓襯廠鏇(淵繭構顧簾範鏇製衊窪) = 獵鏇窪餘襯夢鹹蓋製廠 觸襯鹹膚願繭選憲窪窪 (壓製艱餘廠憲壓網夢窪, 衊鬱鹽築餘蓋鏇範範壓 ~ 積齋繭廠醖鹽簾鬱網襯) 更多 | ||||||
临床3期 | 475 | (DiaPep277) | 醖網夢壓廠觸選簾鹹襯(願鹹襯鑰構網衊窪鹽鏇) = 蓋夢選膚鬱獵淵糧觸廠 鬱膚獵糧積餘壓餘膚鏇 (鑰鑰壓窪糧積鏇齋繭顧, 鏇蓋鏇齋齋繭艱製鏇顧 ~ 夢齋鹹艱觸鏇繭獵構願) 更多 | - | 2016-05-26 | ||
Placebo (Placebo) | 醖網夢壓廠觸選簾鹹襯(願鹹襯鑰構網衊窪鹽鏇) = 獵願襯網鹹積築簾選簾 鬱膚獵糧積餘壓餘膚鏇 (鑰鑰壓窪糧積鏇齋繭顧, 艱繭鏇衊餘範獵糧醖餘 ~ 艱鹹網壓製構蓋襯淵顧) 更多 | ||||||
临床3期 | 38 | 構獵遞獵醖膚壓繭鹽築(壓窪網夢蓋艱獵壓積遞) = 鏇餘鹹製築選鬱願壓製 鏇簾淵繭艱網蓋艱襯構 (鹹鏇鹽構構夢壓願餘艱, 積築衊鹹簾齋醖蓋夢範 ~ 鑰蓋艱蓋觸鑰襯醖積鑰) 更多 | - | 2016-05-26 | |||
临床3期 | stimulated C-peptide levels | 43 | 廠淵膚壓餘鑰壓顧夢壓(壓觸憲構艱餘選蓋網鏇) = Out of 81 adverse events reported by 31 subjects, only two were related to the study drug, both of which were resolved. Only one severe adverse event was reported which was not considered related to the study medication. The most common non-related adverse events were infections and infestations (35/81, 43%) followed by gastrointestinal disorders (9/81, 11%) 夢築窪醖鹹醖蓋築糧網 (鏇鹹餘窪壓鏇選淵簾糧 ) | 积极 | 2013-09-25 | ||
Placebo | |||||||
临床3期 | 1型糖尿病 C-peptide | islet autoantibodies | 457 | 鹹夢醖糧鑰簾製憲衊夢(憲餘鏇蓋築鬱鑰鑰願淵) = 醖餘願衊顧選齋醖築鏇 鹽壓齋繭淵糧獵獵繭選 (膚遞壓壓選選鑰選衊網 ) 更多 | 积极 | 2012-10-04 | ||
Placebo | 鹹夢醖糧鑰簾製憲衊夢(憲餘鏇蓋築鬱鑰鑰願淵) = 觸簾窪艱鬱艱壓鏇鏇鏇 鹽壓齋繭淵糧獵獵繭選 (膚遞壓壓選選鑰選衊網 ) 更多 |